Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 10/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18323502 | 0.87 | SCN10A (0.49) | DHODHNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL15907218 | 0.77 | MTOR (0.43) | DHODHNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL25646846 | 0.75 | DHODH (0.53) | DHODHSCN10ALMNA | |
| SCHEMBL15907173 | 0.72 | SCN10A (0.42) | DHODHNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL15907171 | 0.72 | DHODH (0.48) | DHODHMAPTSMN1; SMN2SCN10ALMNA | |
| SCHEMBL15907169 | 0.71 | DHODH (0.47) | DHODHNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL15907170 | 0.70 | SCN10A (0.46) | DHODHNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL18323501 | 0.70 | KCNQ3 (0.51) | DHODHNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL15907179 | 0.69 | RAB9A (0.52) | NPC1MAPTRAB9ASMN1; SMN2LMNA | |
| SCHEMBL15907174 | 0.68 | DHODH (0.44) | DHODHMAPTSCN10ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | DHODH 3179/4885NPC1 3370/4885MAPT 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.